| Terminated | Controlled Study of Rigosertib Versus Physician's Choice of Treatment in MDS Patients After Failure of an HMA NCT02562443 | Traws Pharma, Inc. | Phase 3 |
| Completed | Reduced Intensity Chemotherapy and Radiation Therapy Before Donor Stem Cell Transplant in Treating Patients Wi NCT02566304 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Phase 2 |
| Completed | Treatment for Relapsed/Refractory AML Based on a High Throughput Drug Sensitivity Assay NCT01872819 | University of Washington | N/A |
| Completed | Efficacy and Safety of IV Rigosertib in MDS Patients With Excess Blasts Progressing After Azacitidine or Decit NCT01928537 | Traws Pharma, Inc. | Phase 3 |
| Completed | Vorinostat, Tacrolimus, and Methotrexate in Preventing GVHD After Stem Cell Transplant in Patients With Hemato NCT01789255 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Idarubicin, Cytarabine, and Pravastatin Sodium in Treating Patients With Acute Myeloid Leukemia or Myelodyspla NCT01831232 | Fred Hutchinson Cancer Center | N/A |
| Terminated | Decitabine Followed by Idarubicin and Cytarabine in Treating Patients With Relapsed or Refractory AML and MDS NCT01607645 | Fred Hutchinson Cancer Center | Phase 2 |
| Completed | Yttrium-90 Anti-CD45 Monoclonal Antibody BC8 Followed by Donor Stem Cell Transplant in Treating Patients With NCT01300572 | Fred Hutchinson Cancer Center | Phase 1 |
| Completed | Clofarabine, Cytarabine, and Filgrastim in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia, Adva NCT01101880 | University of Washington | Phase 2 |
| Completed | Infusion of Off-the-Shelf Expanded Cord Blood Cells to Augment Cord Blood Transplant in Patients With Hematolo NCT01175785 | Nohla Therapeutics, Inc. | Phase 2 |
| Completed | Differentiation Therapy With Decitabine in Treating Patients With Myelodysplastic Syndrome NCT01165996 | Case Comprehensive Cancer Center | Phase 1 / Phase 2 |
| Completed | Donor Peripheral Blood Stem Cell Transplant and Pretargeted Radioimmunotherapy in Treating Patients With High- NCT00988715 | Fred Hutchinson Cancer Center | Phase 1 |
| Completed | Identification of de Novo Fanconi Anemia in Younger Patients With Newly Diagnosed Acute Myeloid Leukemia NCT01146210 | Children's Oncology Group | — |
| Terminated | Iodine I 131 Monoclonal Antibody BC8, Fludarabine Phosphate, Cyclophosphamide, Total-Body Irradiation and Dono NCT00589316 | Fred Hutchinson Cancer Center | Phase 1 |
| Terminated | Busulfan, Etoposide, and Intensity-Modulated Radiation Therapy Followed By Donor Stem Cell Transplant in Treat NCT00540995 | City of Hope Medical Center | Phase 1 / Phase 2 |
| Completed | MS-275 and GM-CSF in Treating Patients With Myelodysplastic Syndrome and/or Relapsed or Refractory Acute Myelo NCT00462605 | National Cancer Institute (NCI) | Phase 2 |
| Completed | A Pilot Study to Evaluate the Co-Infusion of Ex Vivo Expanded Cord Blood Cells With an Unmanipulated Cord Bloo NCT00343798 | Fred Hutchinson Cancer Center | Phase 1 |
| Completed | Fludarabine Phosphate and Total Body Irradiation Followed by a Donor Peripheral Stem Cell Transplant in Treati NCT00397813 | Fred Hutchinson Cancer Center | Phase 2 |
| Completed | Flavopiridol and Vorinostat in Treating Patients With Relapsed or Refractory Acute Leukemia or Chronic Myeloge NCT00278330 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Hematopoietic Stem Cell Transplantation in the Treatment of Infant Leukemia NCT00357565 | Masonic Cancer Center, University of Minnesota | Phase 2 |
| Completed | Lenalidomide in Treating Young Patients With Relapsed or Refractory Solid Tumors or Myelodysplastic Syndromes NCT00104962 | National Cancer Institute (NCI) | Phase 1 |
| Completed | SB-715992 in Treating Patients With Acute Leukemia, Chronic Myelogenous Leukemia, or Advanced Myelodysplastic NCT00098826 | National Cancer Institute (NCI) | Phase 1 |
| Completed | XK469R in Treating Patients With Refractory Hematologic Cancer NCT00095797 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Idarubicin, Cytarabine, and Tipifarnib in Treating Patients With Newly Diagnosed Myelodysplastic Syndromes or NCT00096122 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Completed | Rebeccamycin Analog in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic S NCT00087204 | National Cancer Institute (NCI) | Phase 1 |
| Completed | CCI-779 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, NCT00084916 | National Cancer Institute (NCI) | Phase 2 |
| Terminated | Iodine I 131 Monoclonal Antibody BC8, Fludarabine Phosphate, Total Body Irradiation, and Donor Stem Cell Trans NCT00119366 | Fred Hutchinson Cancer Center | Phase 2 |
| Completed | Biological Therapy in Treating Patients With Advanced Myelodysplastic Syndrome, Acute or Chronic Myeloid Leuke NCT00052520 | Fred Hutchinson Cancer Center | Phase 1 / Phase 2 |
| Completed | Tipifarnib in Treating Patients With Myelodysplastic Syndromes NCT00005845 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Thalidomide in Treating Patients With Myelodysplastic Syndrome NCT00015990 | National Cancer Institute (NCI) | Phase 2 |
| Completed | BMS-214662 in Treating Patients With Acute Leukemia, Myelodysplastic Syndrome, or Chronic Myeloid Leukemia NCT00006213 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Liposomal Daunorubicin and SU5416 in Treating Patients With Hematologic Cancer That Has Not Responded to Initi NCT00005942 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Completed | PS-341 in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, NCT00005064 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Vaccine Therapy Plus Immune Adjuvant in Treating Patients With Chronic Myeloid Leukemia, Acute Myeloid Leukemi NCT00004918 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Completed | Radiolabeled Monoclonal Antibody Therapy, Fludarabine Phosphate, and Low-Dose Total-Body Irradiation Followed NCT00008177 | Fred Hutchinson Cancer Center | Phase 1 |
| Completed | Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Children With Acute Myelogeno NCT00002798 | National Cancer Institute (NCI) | Phase 3 |